POOLBEG PHARMA PLC
Clinical-stage biopharma using AI to identify drug targets for unmet medical needs.
POLB | IL
Overview
Corporate Details
- ISIN(s):
- GB00BKPG7Z60
- LEI:
- 213800UZ8WJLWYHBFL52
- Country:
- United Kingdom
- Address:
- QUEEN MARY BIOENTERPRISES INNOVATION CENTRE, E1 2AX LONDON
- Website:
- https://poolbegpharma.com/
- Sector:
- Manufacturing
Description
Poolbeg Pharma PLC is a clinical-stage biopharmaceutical company that develops and commercializes medicines for diseases with high unmet medical needs. The company's lead asset, POLB 001, is a treatment designed to prevent Cytokine Release Syndrome (CRS), a severe side effect associated with cancer immunotherapies, with the aim of making these treatments safer and more accessible. Poolbeg is also advancing an oral GLP-1 program for obesity, offering a patient-friendly therapeutic option. The company utilizes an artificial intelligence (AI)-led discovery platform that analyzes data from human challenge trials to identify novel drug targets. This AI-driven approach aims to accelerate target identification, reduce costs, and lower development risks.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Type / Size | Actions | |
|---|---|---|---|---|---|
| 2025-12-18 08:25 |
Letter to Shareholders – 2025 a year of progress
|
English | HTML • 23.1 KB | ||
| 2025-12-08 08:35 |
POLB 001 to feature in CRS research programme
|
English | HTML • 21.7 KB | ||
| 2025-11-20 08:25 |
POLB 001 European Patent granted
|
English | HTML • 15.2 KB | ||
| 2025-09-29 08:00 |
Interim Results for the six months to 30 June 2025
|
English | HTML • 155.8 KB | ||
| 2025-09-25 08:00 |
POLB 001 Phase 2a Trial Update
|
English | HTML • 24.3 KB | ||
| 2025-07-01 17:24 |
Notification of Major Holdings
|
English | HTML • 43.8 KB | ||
| 2025-06-26 08:00 |
Notification of Major Holdings
|
English | HTML • 66.7 KB | ||
| 2025-06-25 09:00 |
Director/PDMR Shareholding
|
English | HTML • 29.8 KB | ||
| 2025-06-23 15:57 |
Results of GM and AGM Meetings
|
English | HTML • 16.0 KB | ||
| 2025-05-27 08:01 |
FDA Orphan Drug Designation granted for POLB 001
|
English | HTML • 18.0 KB | ||
| 2025-05-27 08:00 |
Annual Report, AGM Notice & Circular
|
English | HTML • 16.2 KB | ||
| 2025-05-23 08:00 |
Result of upsized oversubscribed BookBuild Offer
|
English | HTML • 26.8 KB | ||
| 2025-05-22 14:44 |
Increase of BookBuild Offer
|
English | HTML • 35.6 KB | ||
| 2025-05-20 13:26 |
Result of Placing and Notice of General Meeting
|
English | HTML • 33.2 KB | ||
| 2025-05-20 08:02 |
Proposed Retail Offer to raise up to £100,000
|
English | HTML • 55.8 KB |
Automate Your Workflow. Get a real-time feed of all POOLBEG PHARMA PLC filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for POOLBEG PHARMA PLC
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for POOLBEG PHARMA PLC via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
